Our international activities date back to the 1990s when the company won its first major tender and placed its products in the private market with the aid of selected partners.

Today, we continue to work towards establishing successful alliances and becoming the partner of choice for innovative and branded generics worldwide. In order to achieve this, the goal of our International Business Division is to explore all possible collaborations related to ELPEN's products through flexible business models and always supported by ELPEN's departments of R&D, Production, Quality Assurance, Patents, and Regulatory Affairs.

ELPEN's portfolio includes Rx and OTC products from therapeutic areas such as:

  • Respiratory
  • Cardiometabolics
  • Cardiology
  • Central Nervous System
  • Metabolic Disorders
  • Infectious diseases
  • Gastroinstestinal disorders
  • Musculoskeletal Disorders
  • Skin Care

Our products are commercialized in five continents, including the following countries:


Our continous contact with key opinion leaders enables us to develop new pharmaceutical forms and combinations that provide benefits for patients and healthcare systems.

To find out more about our products, please contact us at bdgen@elpen.gr